Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
NCT04842370
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Relapsed or Refractory Acute Myeloid Leukemia
Interventions
DRUG:
PHI-101
Sponsor
Seoul National University Hospital
Collaborators
[object Object]